Otsuka (OTCMKTS:OTSKY) & Synaptogenix (NASDAQ:TAOX) Head to Head Survey

Otsuka (OTCMKTS:OTSKY) and Synaptogenix (NASDAQ:TAOX) are both healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, valuation, analyst recommendations, dividends, risk, institutional ownership and earnings.

Institutional and Insider Ownership

10.3% of Synaptogenix shares are held by institutional investors. 2.7% of Synaptogenix shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Volatility & Risk

Otsuka has a beta of 0.09, indicating that its share price is 91% less volatile than the S&P 500. Comparatively, Synaptogenix has a beta of 1.73, indicating that its share price is 73% more volatile than the S&P 500.

Profitability

This table compares Otsuka and Synaptogenix’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Otsuka	15.50%	12.86%	9.59%
Synaptogenix	-2,153.97%	-128.51%	-97.54%

Valuation & Earnings

This table compares Otsuka and Synaptogenix”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Otsuka	$16.51 billion	2.35	$2.43 billion	$2.49	14.53
Synaptogenix	$772,499.00	38.36	-$28.74 million	($3.85)	-1.03

Otsuka has higher revenue and earnings than Synaptogenix. Synaptogenix is trading at a lower price-to-earnings ratio than Otsuka, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of current recommendations and price targets for Otsuka and Synaptogenix, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Otsuka	1	2	1	0	2.00
Synaptogenix	1	0	0	0	1.00

Summary

Otsuka beats Synaptogenix on 9 of the 13 factors compared between the two stocks.

About Otsuka

Otsuka Holdings Co., Ltd. engages in the pharmaceuticals, nutraceuticals, consumer products, and other businesses worldwide. The company develops pharmaceutical products in the fields of psychiatry, neurology, oncology, cardiovascular and renal system, digestive system, ophthalmology, and diagnostics, as well as intravenous solutions and medical devices. It also provides clinical testing, medical equipment, food products, cosmetics, functional food products, chemical products, soft drinks, beverages, analytical and measurement instruments, nutritional products, vehicle headlight testers, synthetic resin molded products, paper products, and insecticide and toiletry products. In addition, the company offers IT solution services; adhesive tapes; flaky titanate and compounds; IV solutions; infusion and clinical nutrition products; hydrazine; plant-based food products; reinsurance underwriting services; wine; stable isotopes; food supplements; urinary tract health products; software and services for management of mental healthcare systems; anticancer drugs; terracess; bio-pesticides; dietetic food products; spring and mineral water; and polyolefin foams. Further, it engages in the warehousing and transport, medical device operational management, shared service, environmental health management, and venture capital and incubation businesses; rental of medical devices and related products; purchase and sale of agricultural products; import and export trading business; tuberculosis research and development activities; manufacturing and development of xenotransplantation products; and processing and marketing of functional films, as well as planning, design, production, and construction of ceramic boards and arts, ceramic walls, reliefs, terracotta, ceramic OT and portraits, and ceramic sign boards; and operation of travel agency, and Hotel Ridge and California Table. Otsuka Holdings Co., Ltd. was founded in 1921 and is headquartered in Tokyo, Japan.

About Synaptogenix

Synaptogenix, Inc. operates as a biopharmaceutical company with product candidates in pre-clinical and clinical development. It focuses on developing a product platform based upon a drug candidate called Bryostatin-1 for the treatment of Alzheimer’s disease. The company is also evaluating therapeutic applications of bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as fragile X syndrome, multiple sclerosis, and Niemann-pick type C disease. Synaptogenix, Inc. has licensing agreements with Stanford University; Icahn School of Medicine at Mount Sinai; and The Board of Trustees of the Leland Stanford Junior University. The company was incorporated in 2012 and is headquartered in New York, New York.